Hypertrophic Cardiomyopathy
Conditions
Interventions
Mavacamten Group:None
Non-Mavacamten Group:None
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. According to the AHA/ACC/AMSSM / 2024 HRS/secondary/SCMR hypertrophic cardiomyopathy guide diagnosed with obstructive HCM. 2. Age: >=18 years old 3. Genetic testing related to hypertrophic cardiomyopathy has been completed, excluding other hypertrophic phenotype heart diseases (such as Fabre's disease, amyloid cardiomyopathy, etc.)
Exclusion criteria
Exclusion criteria: 1. Patients who were unable to complete the study follow-up plan and lacked follow-up data; 2. Patients lacking imaging data (including echocardiography, coronary CT, cardiac enhanced magnetic resonance imaging (MRI), and fibroblast activating protein inhibitor (FAPI) imaging); 3. A combination of acute or chronic medical or psychiatric conditions, including recent (within the past year) combination of active suicidal ideation or behavior or abnormalities in laboratory tests, that may increase the risk of adverse events for study participants or interfere with study findings, and are judged by the investigator to be unsuitable for inclusion in the study; 4. Women who are pregnant or breastfeeding; 5. Consider patients with other hypertrophic phenotype cardiomyopathy (such as hypertensive, amyloidosis, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction;Left ventricular outflow tract pressure;Cardiac biomarker;Myocardial strain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Kansas City cardiomyopathy questionnaire score; | — |
Countries
China
Contacts
Public ContactYing Liu
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed